GMP violations prompt U.S. FDA warning against 2 Indian drugmakers

08/25/2013 | Economic Times (India), The

Indian drugmakers Posh Chemicals and Promed Exports received warning letters from the U.S. FDA that indicated breaches in good manufacturing practices. Six India-based drug facilities have received the notices in the past three months. Lupin Pharma CEO Vinita Gupta said "all the FDA is trying to do is differentiate the good manufacturers from the not-so-good ones. Indian manufacturers are not being targeted."

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA